Histopathology and cytopathology of cervical cancer

Disease Markers

Volumn 23, Issue 4, 2007, Pages 199-212

  Jenkins, David ^a,b  

^a GSK   (Belgium)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ACCURACY; ADENOCARCINOMA; CANCER CLASSIFICATION; CANCER INVASION; CANCER SCREENING; CARCINOGENESIS; CARCINOMA IN SITU; CLINICAL PRACTICE; CLINICAL RESEARCH; COHORT ANALYSIS; CYTOPATHOLOGY; DIAGNOSTIC TEST; HISTOPATHOLOGY; HISTORY; HUMAN; MEDICAL LITERATURE; NOMENCLATURE; PRECANCER; PRECURSOR; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

EID: 34347352266     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/874795     Document Type: Review

References (79)

1. M.E. van den Akker-van Marle, M. van Ballegooijen, G.J. van Oortmarssen, R. Boer and J.D. Habbema, Cost-effectiveness of cervical cancer screening: comparison of screening policies, J Natl Cancer Inst 94 (2002), 193-204.
2. A. Anttila, G. Ronco, G. Clifford, F. Bray, M. Hakama, M. Arbyn et al., Cervical cancer screening programmes and policies in 18 European countries, Br J Cancer 91 (2004), 935-941.
3. J. Peto, C. Gilham, O. Fletcher and F.E. Matthews, The cervical cancer epidemic that screening has prevented in the UK, Lancet 364 (2004), 249-256.
4. R.M. Richart, Natural history of cervical intraeithelial neoplasia, Clin Obstet Gynecol (1968), 5.
5. R.M. Richart, Cervical intraepithelial neoplasia, Pathol Annu 8 (1973), 301-328.
6. B. Anderson, Premalignant and malignant squamous lesions of the cervix, in: Haines and Taylor: Obstetrical and Gynaecological Pathology, H. Fox, ed., 1995, pp. 273-322.
7. P. Virtej and C. Vasiliu, Cytodiagnosis in cervical neoplasia: from the Babes/Papanicolaou smear to the actual Bethesda System, Clin Exp Obstet Gynecol 30 (2003), 173-177.
8. G.N. Papanicolaou and H.F. Traut, The diagnostic value of vaginal smears in carcinoma of the uterus. 1941, Arch Pathol Lab Med 121 (1997), 211-224.
9. M.C. Anderson, C.L. Brown, C.H. Buckley, H. Fox, D. Jenkins, D.G. Lowe et al., Current views on cervical intraepithelial neoplasia, J Clin Pathol 44 (1991), 969-978.
10. N. Munoz, X. Castellsague, A.B. de Gonzalez and L. Gissmann, Chapter 1: HPV in the etiology of human cancer, Vaccine 24 (2006), S3:S1-S10.
11. M. Stanley, Immune responses to human papillomavirus, Vaccine (2005).
12. S.K. Tay, D. Jenkins, P. Maddox, M. Campion and A. Singer, Subpopulations of Langerhans' cells in cervical neoplasia, Br J Obstet Gynaecol 94 (1987), 10-15.
13. Histopathology Reporting in Cervical Screening, Ed. Fox H & Buckley CH. NHSCSP Publication 10, 1999, Sheffield ISBN 1 871997 68 2.
14. D. Jenkins, The pathology of lower genital tract premalignancy, Clin Pract Gynaecol (1987).
15. M. Stoler, The pathology of cervical neoplasia, Kluwer Academic Publishers, 2004.
16. D. Solomon, The 1988 Bethesda system for reporting cervical/vaginal cytological diagnoses, Acta Cytologica (1989).
17. D. Solomon, D.Davey, R.Kurman, A. Moriarty, D. O'Connor, M. Prey et al., The 2001 Bethesda System: terminology for reporting results of cervical cytology, JAMA 287 (2002), 2114-2119.
18. C. Bergeron, The 2001 Bethesda system, Salud Publica Mex 45(Suppl 3) (2003), S340-S344.
19. D. Jenkins, S.K. Tay, D.J. McCance, M.J. Campion, P.K. Clarkson and A. Singer, Histological and immunocytochemical study of cervical intraepithelial neoplasia (CIN) with associated HPV 6 and HPV 16 infections, J Clin Pathol 39 (1986), 1177-1180.
20. M.H. Stoler and M. Schiffman, Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study, JAMA 285 (2001), 1500-1505.
21. K. Middleton, W. Peh, S. Southern, H. Griffin, K. Sotlar, T. Nakahara et al., Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers, J Virol 77 (2003), 10186-10201.
22. J.T. Cox, M. Schiffman and D. Solomon, Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy, Am J Obstet Gynecol 188 (2003), 1406-1412.
23. A.B. Moscicki, S. Shiboski, N.K. Hills, K.J. Powell, N. Jay, E.N. Hanson et al., Regression of low-grade squamous intraepithelial lesions in young women, Lancet 364 (2004), 1678-1683.
24. A. Szarewski and P. Sasieni, Cervical screening in adolescents-at least do no harm, Lancet 364 (2004), 1642-1644.
25. S.S. Wang, M. Trunk, M. Schiffman, R. Herrero, M.E. Sherman, R.D. Burk et al., Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica, Cancer Epidemiol Biomarkers Prev 13 (2004), 1355-1360.
26. P. Tidbury, A. Singer and D. Jenkins, CIN 3: the role of lesion size in invasion, Br J Obstet Gynaecol 99 (1992), 583-586.
27. M.E. Sherman, S.S. Wang, R. Tarone, L. Rich and M. Schiffman, Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the atypical squamous cells of undetermined significance low-grade squamous intraepithelial lesion triage study: implications for subject safety and lead-time bias, Cancer Epidemiol Biomarkers Prev 12 (2003), 372-379.
28. M.E. Sherman, S.S. Wang, C.M. Wheeler, L. Rich, P.E. Gravitt, R. Tarone et al., Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions, Cancer Epidemiol Biomarkers Prev 12 (2003), 1038-1044.
29. M.R. Jarmulowicz, D. Jenkins, S.E. Barton, A.L. Goodall, A. Hollingworth and A. Singer, Cytological status and lesion size: a further dimension in cervical intraepithelial neoplasia, Br J Obstet Gynaecol 96 (1989), 1061-1066.
30. A.I. al Nafussi and D.E. Hughes, Histological features of CIN3 and their value in predicting invasive microinvasive squamous carcinoma, J Clin Pathol 47 (1994), 799-804.
31. N.R. Griffin and M. Wells, Premalignant and malignant glandular lesions of the cervix, Edinburgh, Churchill Livingstone, 1995.
32. D.M. Parkin and F. Bray, Chapter 2: The burden of HPV-related cancers, Vaccine 24(Suppl 3) (2006), S11-S25.
33. C.H. Buckley, Tumors of the cervix uteri, Edinburgh, Churchill Livingstone, 1995.
34. J.H. Shepherd, Revised FIGO staging for gynaecological cancer, Br J Obstet Gynaecol 96 (1989), 889-892.
35. J.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A.Kummer, K.V. Shah et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J Pathol 189 (1999), 12-19.
36. C.J. Lacey, C.M. Lowndes and K.V. Shah, Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease, Vaccine 24(Suppl 3) (2006), S35-S41.
37. E. Burghardt, F. Girardi, M. Lahousen, H. Pickel and K. Tamussino, Microinvasive carcinoma of the uterine cervix (International Federation of Gynecology and Obstetrics Stage IA), Cancer 67 (1991), 1037-1045.
38. N. Tsukamoto, T. Kaku, K. Matsukuma, T. Matsuyama, T. Kamura, T. Saito et al., The problem of stage Ia (FIGO, 1985) carcinoma of the uterine cervix, Gynecol Oncol 34 (1989), 1-6.
39. F. Girardi et al., Small FIGO stage Ib cervical cancer, Gynecologic Oncology (1994).
40. S.M. Ismail, Cone biopsy causes cervical endometriosis and tubo-endometrioid metaplasia, Histopathology 18 (1991), 107-114.
41. A. al Nafussi and M. Rahilly, The prevalence of tubo-endometrial metaplasia and adenomatoid proliferation, Histopathology 22 (1993), 177-179.
42. J.A. Ferry and R.E. Scully, Mesonephric remnants, hyperplasia, and neoplasia in the uterine cervix. A study of 49 cases, Am J Surg Pathol 14 (1990), 1100-1111.
43. D.R. Scott, B. Hagmar, P. Maddox, A. Hjerpe, J. Dillner, J. Cuzick et al., Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom, Cancer 96 (2002), 14-20.
44. M.T. Fahey, L. Irwig and P. Macaskill, Meta-analysis of Pap test accuracy, Am J Epidemiol 141 (1995), 680-689.
45. K. Nanda, D.C. McCrory, E.R. Myers, L.A. Bastian, V. Hasselblad, J.D. Hickey et al., Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review, Ann Intern Med 132 (2000), 810-819.
46. J. Cuzick, M.H. Mayrand, G. Ronco, P. Snijders and J. Wardle, Chapter 10: New dimensions in cervical cancer screening, Vaccine 24(Suppl 3) (2006), S90-S97.
47. M. Arbyn, F. Buntinx, M. Van Ranst, E. Paraskevaidis, P. Martin-Hirsch and J. Dillner, Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia, J Natl Cancer Inst 96 (2004), 280-293.
48. M. Arbyn, P. Sasieni, C.J. Meijer, C. Clavel, G. Koliopoulos and J. Dillner, Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses, Vaccine 24(Suppl 3) (2006), S78-S89.
49. M.E. Sherman, M. Schiffman, R. Herrero, D. Kelly, C. Bratti, L.J. Mango et al., Performance of a semiautomated Papanicolaou smear screening system: results of a population-based study conducted in Guanacaste, Costa Rica, Cancer 84 (1998), 273-280.
50. S.J. Goldie, D. Grima, M. Kohli, T.C. Wright, M. Weinstein and E. Franco, Acomprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine, Int J Cancer 106 (2003), 896-904.
51. S.J. Goldie, M. Kohli, D. Grima, M.C. Weinstein, T.C. Wright, F.X. Bosch et al., Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine, J Natl Cancer Inst 96 (2004), 604-615.
52. J. Melnikow, J. Nuovo, A.R. Willan, B.K. Chan and L.P. Howell, Natural history of cervical squamous intraepithelial lesions: a meta-analysis, Obstet Gynecol 92 (1998), 727-735.
53. J.D. Wright, R.M. Davila, K.R. Pinto, D.F. Merritt, R.K. Gibb, J.S. Rader et al., Cervical dysplasia in adolescents, Obstet Gynecol 106 (2005), 115-120.
54. G.M. Clifford, J.S. Smith, M. Plummer, N. Muñoz and S. Franceschi, Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis, Br J Cancer 88 (2003), 63-73.
55. G.M. Clifford, J.S. Smith, T. Aguado and S. Franceschi, Comparison of HPVtype distribution in high-grade cervical lesions and cervical cancer: a meta-analysis, Br J Cancer 89 (2003), 101-105.
56. G. Clifford, S. Franceschi, M. Diaz, N. Munoz and L.L. Villa, Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases, Vaccine 24(Suppl 3) (2006), S26-S34.
57. S. Franceschi and G.M. Clifford, Re: A study of the impact of adding HPV types to cervical cancer screening and triage tests, J Natl Cancer Inst 97 (2005), 938-939.
58. G.M. Clifford, R.K. Rana, S. Franceschi, J.S. Smith, G. Gough and J.M. Pimenta, Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer, Cancer Epidemiol Biomarkers Prev 14 (2005), 1157-1164.
59. L.A. Koutsky, K.K. Holmes, C.W. Critchlow, C.E. Stevens, J. Paavonen, A.M. Beckmann et al., A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection, N Engl J Med 327 (1992), 1272-1278.
60. D.M. Harper, E.L. Franco, C. Wheeler, D.G. Ferris, D. Jenkins, A. Schuind et al., Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, Lancet 364 (2004), 1757-1765.
61. R.L. Winer, N.B. Kiviat, J.P. Hughes, D.E. Adam, S.K. Lee, J.M. Kuypers et al., Development and duration of human papillomavirus lesions, after initial infection, J Infect Dis 191 (2005), 731-738.
62. H. Trottier, S. Mahmud, L. Lindsay, D. Jenkins, S. Wieting and E. Franco, Natural history of HPV infection and cervical lesions in women from the placebo arm of an AS04 adjuvanted HPV-16/18 L1 vaccine trial. EUROGIN.
63. A.B. Moscicki, M. Schiffman, S. Kjaer and L.L.Villa, Chapter 5: Updating the natural history of HPV and anogenital cancer, Vaccine 24(Suppl 3) (2006), S42-S51.
64. H.C. Kitchener, P.E. Castle and J.T. Cox, Chapter 7: Achievements and limitations of cervical cytology screening, Vaccine 24(Suppl 3) (2006), S63-S70.
65. J.P. Bory, J. Cucherousset, M. Lorenzato, R. Gabriel, C. Quereux, P. Birembaut et al., Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women, Int J Cancer 102 (2002), 519-525.
66. V. Dalstein, D. Riethmuller, J.L. Pretet, C.K. Le Bail, J.L. Sautiere, J.P. Carbillet et al., Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study, Int J Cancer 106 (2003), 396-403.
67. N.F. Schlecht, S. Kulaga, J. Robitaille, S. Ferreira, M. Santos, R.A. Miyamura et al., Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia, JAMA 286 (2001), 3106-3114.
68. G.Y. Ho, R.D. Burk, S. Klein, A.S. Kadish, C.J. Chang, P. Palan et al., Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia, J Natl Cancer Inst 87 (1995), 1365-1371.
69. K.L. Wallin, F. Wiklund, T. Angstrom, F. Bergman, U. Stendahl, G. Wadell et al., Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer, N Engl J Med 341 (1999), 1633-1638.
70. M.J. Khan, P.E. Castle, A.T. Lorincz, S. Wacholder, M. Sherman, D.R. Scott et al., The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice, J Natl Cancer Inst 97 (2005), 1072-1079.
71. P.E. Castle, D. Solomon, M. Schiffman and C.M. Wheeler, Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities, J Natl Cancer Inst 97 (2005), 1066-1071.
72. M. Hicks and M. Piver, How to obtain an accurate pap smear, Med Asp Human Sexuality (1991).
73. D. Jenkins, Public Health issues related to HPV vaccination, in: Emerging issues on HPV infections from science to practice, J. Monsonego, ed., Karger, 2006.
74. S.J. Goldie, J.D. Goldhaber-Fiebert and G.P. Garnett, Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling, Vaccine 24(Suppl 3) (2006), S155-S163.
75. S.J. Goldie, J.J. Kim and E. Myers, Chapter 19: Cost-effectiveness of cervical cancer screening, Vaccine 24(Suppl 3) (2006), S164-S170.
76. L.A. Koutsky, K.A. Ault, C.M. Wheeler, D.R. Brown, E. Barr, F.B. Alvarez et al., A controlled trial of a human papillomavirus type 16 vaccine, N Engl J Med 347 (2002), 1645-1651.
77. C. Mao, L.A. Koutsky, K.A. Ault, C.M. Wheeler, D.R. Brown, D.J. Wiley et al., Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial, Obstet Gynecol 107 (2006), 18-27.
78. D.M. Harper, E.L. Franco, C.M. Wheeler, A.B. Moscicki, B. Romanowski, C.M. Roteli-Martins et al., Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial, Lancet 367 (2006), 1247-1255.
79. E.L. Franco, J. Cuzick, A. Hildesheim and S. de Sanjose, Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination, Vaccine 24(Suppl 3) (2006), S171-S177.